News | December 07, 2021
Study shows Glaxo-Vir drug works against Omicron mutations
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
The hospital is scheduled to open in 2024 with a bed capacity of 225
The fund aims at investing in companies that extends human healthspan
The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
The Omicron variant doesn't escape RTPCR and RAT; States advised to ramp up testing for prompt and early identification of any cases
Subscribe To Our Newsletter & Stay Updated
